Teva: Falling Debt, Falling EBITDA, Struggles Continue

Summary

  • Teva is continuing to shrink to deleverage its balance sheet.
  • While absolute debt levels are coming down, leverage ratios are largely 'intact' because of a declining business.
  • Stabilization is required, certainly if opioid claims might become a reality as well.
  • Looking for a community to discuss ideas with? Value In Corporate Events features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today ยป

Teva Pharmaceutical (TEVA) is a name which has seen continued tough times as it is dealing with a high debt load and massive sales pressure on its most important drug, as well as a generally not favourable pricing environment.

While the company delivered on its 2018 plans, it is a softer first quarter for 2019 and potential overhang from claims related to the opioid crisis which is causing overhang on the shares, making investors really cautious. While this could provide an opportunity, this remains a highly risky and long-term recovery story with still an uncertain outcome.

The Old Thesis

Lots of major developments have put Teva in the state in which it is today, as the company has seen tough times in recent years. Last time I looked at the firm was May of 2018 as I looked at the prospects for the company after CEO Kare Schultz had just taken the top spot.

The struggles faced by Teva stem directly from the $40 billion purchase of the generics business of Allergan (AGN) after big-pharma dealmaking took place around 2015 and Teva was a willing participant in this. The acquired activities did not quickly meet up to the standards and expectations. On top of this dramatic generics deal, Teva has been hit by ironically enough generic competition for its own blockbuster Copaxone.

When this situation became clear, we have to give some credit to Teva. Mr. Schultz quickly resorted to asset sales, as well as job losses totaling 14,000 workers, all aimed to cut the huge net debt load.

READ FULL ARTICLE HERE